112 results
8-K/A
EX-99.1
GMDAQ
Gamida Cell Ltd
5 Apr 24
Other Events
5:16pm
and who had no available matched donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT … %) and a safety profile similar to that reported previously.
On April 26, 2022, the Company announced that the FDA cleared its investigational new drug
8-K
EX-99.1
87ninl 9wwgez1x8o76
14 Nov 23
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
12:00am
8-K
EX-99.1
e6jtq55zo9jog
27 Sep 23
Regulation FD Disclosure
4:43pm
8-K
EX-1.1
ealta9eucww6 f6ajhf2
21 Apr 23
Gamida Cell Announces Launch of Public Offering of Securities
7:19am
8-K
EX-99.1
7e4179u 64risn
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
8-K
EX-99.1
uaer26l3f zab8mx
12 Dec 22
Gamida Cell Announces Closing of $25 Million Financing with Highbridge
7:15am
8-K
EX-99.1
swzpj5gn
21 Nov 22
Gamida Cell Provides Regulatory Update on Omidubicel
5:20pm
8-K
EX-99.1
du8qdqz tsj
14 Nov 22
Gamida Cell Reports Third Quarter 2022 Financial Results
7:15am
8-K
EX-1.1
r0etmj
30 Sep 22
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
4:02pm
424B5
m4zrru
29 Sep 22
Prospectus supplement for primary offering
4:08pm